3-Ethyl-1-methyl-imidazolidine-2,4-dione | 71300-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-Ethyl-1-methyl-imidazolidine-2,4-dione
• 英文别名: 3-Ethyl-1-methylimidazolidine-2,4-dione
• CAS: 71300-02-2
• 化学式: C₆H₁₀N₂O₂
• mdl: MFCD12193068
• 分子量: 142.158
• InChiKey: VFJNVGKMKGPHSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-methylhydantoin anion 、 碘乙烷 以 乙腈 为溶剂， 生成 3-Ethyl-1-methyl-imidazolidine-2,4-dione
  参考文献：
  名称：

  Kondo, Yasuhiko; Tsukamoto, Tamio; Kimura, Naoko, Journal of the Chemical Society. Perkin Transactions 2 (2001), 1997, # 9, p. 1765 - 1769

  摘要：

  DOI：

文献信息

• FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE
  申请人：ESPERVITA THERAPEUTICS, INC.

  公开号：US20210024447A1

  公开（公告）日：2021-01-28

  This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

  这项发明提供了Formulae（IA）、（IB）、（IC）、（ID）、（IE）、（IF）、（IG）、（IH）、（IJ）、（IK）、（IL）、（II）、（III）、（IIIA）和（IIIB）的化合物；这些化合物的药学上可接受的盐和溶剂；以及它们的组合物。这项发明还提供了治疗疾病的方法，包括但不限于肝病或异常肝脏状况；癌症（如肝细胞癌或胆管癌）；肺、肝、胆囊、胆管或消化道的恶性或良性肿瘤；肝内或肝外胆管疾病；脂蛋白紊乱；脂质和代谢紊乱；肝硬化；纤维化；葡萄糖代谢紊乱；心血管或相关血管紊乱；由脂肪变性、纤维化或肝硬化引起的疾病；与炎症增加有关的疾病（如肝炎或肺炎炎症）；肝细胞球形变；过氧化物酶体增殖子激活受体相关的疾病；ATP柠檬酸裂合酶疾病；乙酰辅酶A羧化酶疾病；肥胖；胰腺炎；或肾脏疾病。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
  申请人：Fang Qun Kevin

  公开号：US20110166146A1

  公开（公告）日：2011-07-07

  Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.

  本发明揭示了咪唑并[1,2-a]吡啶类化合物。该发明的化合物是有用的治疗剂，揭示了它们在制药配方中的包含以及在治疗方法中的使用。
• Process for preparing methylolhydantoins
  申请人：LONZA INC.

  公开号：EP0571904A1

  公开（公告）日：1993-12-01

  There are provided methods for producing solid anhydrous methylolhydantoins. Initially, an aqueous stirrable medium is dehydrated and heated to yield a substantially anhydrous stirrable melt. The aqueous stirrable medium includes (A) a solute selected from the group consisting of (i) a dimethyloldimethylhydantoin, (ii) a hydantoin reactant, (iii) a formaldehyde source reactant, or (iv) a combination of any of the foregoing; and (B) optionally a catalyst. A molten system is then provided by adding, to the stirrable melt, a reactant mixture which includes (A)(i) the same or a different hydantoin reactant, (ii) a substantially anhydrous formaldehyde source reactant which may be the same as or different than the formaldehyde source reactant, or (iii) a combination thereof; and (B) optionally, the same or a different catalyst; wherein the molten system includes (i) at least one hydantoin reactant and (ii) at least one dehydrated formaldehyde source reactant or substantially anhydrous formaldehyde source reactant. The at least one hydantoin reactant and the at least one dehydrated formaldehyde source reactant or substantially anhydrous formaldehyde source reactant in the molten system are reacted, while reaction water is removed, to yield anhydrous molten methylolhydantoin. Finally, the molten methylolhydantoin is solidified. Alternatively, solid anhydrous methylolhydantoin is produced by reacting, in an aqueous stirrable medium as above, a reactant mixture of (i) the same or a different hydantoin reactant, (ii) a substantially anhydrous formaldehyde source reactant which may be the same as or different than the formaldehyde source reactant, or (ii) a combination thereof and (iv) optionally, the same as or different catalyst; wherein (i) at least one hydantoin reactant and (ii) at least one formaldehyde source reactant or substantially anhydrous formaldehyde reactant is present; while heating to at least the melting temperature of the methylolhydantoin and while removing substantially all water; to yield a molten methylolhydantoin; and subsequently solidifying the molten methylolhydantoin. These methods can be practiced as batch processes or as semi-continuous processes.

  本发明提供了生产固体无水甲基海因的方法。首先，对含水可搅拌介质进行脱水和加热，以得到基本无水的可搅拌熔体。水性可搅拌介质包括：(A) 选自以下组别的溶质：(i) 二甲基二羟甲基海因，(ii) 海因反应物，(iii) 甲醛源反应物，或 (iv) 上述任一物质的组合；以及 (B) 可选催化剂。然后通过向可搅拌熔体中加入反应物混合物来提供熔融体系，该反应物混合物包括 (A)(i)相同或不同的海因反应物，(ii)与甲醛源反应物相同或不同的基本无水甲醛源反应物，或 (iii) 上述反应物的组合；(B) 可选地，相同或不同的催化剂；其中熔融体系包括 (i) 至少一种海因反应物和 (ii) 至少一种脱水甲醛源反应物或基本无水甲醛源反应物。熔融体系中的至少一种海因反应物和至少一种脱水甲醛源反应物或基本无水甲醛源反应物发生反应，同时除去反应水，生成无水熔融甲基海因。最后，将熔融的甲基海因固化。另一种方法是，在上述水性可搅拌介质中，通过以下反应物混合物反应制得固态无水甲基海因：(i) 相同或不同的海因反应物；(ii) 与甲醛源反应物相同或不同的基本无水甲醛源反应物；或 (ii) 它们的组合；(iv) 可选的相同或不同的催化剂；其中(i)至少存在一种海因反应物和(ii)至少存在一种甲醛源反应物或基本无水的甲醛反应物；同时加热至至少甲醇海因的熔化温度，并除去基本所有的水；得到熔融的甲醇海因；随后将熔融的甲醇海因凝固。这些方法可以分批进行，也可以半连续进行。
• Kondo, Yasuhiko; Nonaka, Osamu; Iwasaki, Kazuhiko, Journal of the Chemical Society. Perkin transactions II, 1994, # 3, p. 473 - 478
  作者：Kondo, Yasuhiko、Nonaka, Osamu、Iwasaki, Kazuhiko、Kuwamoto, Tomoyuki、Takagi, Tatsuya

  DOI：——

  日期：——
• EP1730142B1
  申请人：——

  公开号：EP1730142B1

  公开（公告）日：2011-06-29